Further Enhances Research Capabilities in Infectious Disease and BiodefenseDURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American:...
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company”...
DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...
AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as...
BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 23, 2022...
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against...
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children...
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in...
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — —...
The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a...
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Two-decade industry veteran joined Elevar as VP of finance in January Elevar Therapeutics Names Wade Smith Chief Financial Officer Wade...
DCBY02 to be assessed in patients with advanced or metastatic solid tumors across dose-escalation and dose-expansion parts of a Phase...
MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22,...
Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via...
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present...
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...